Market opportunity for colistin potentiators Challenge A Spanish university spinout with an integrated platform to discover and develop new antimicrobials and adjuvants with novel mechanisms of action, was advancing a potentiator program that involves the development of adjuvant candidates to enhance the activity of a last-resort antibiotic. The university was conducting proof-of-concept (PoC) studies for this lead program, due for completion by December 2018. In the meantime, the spinout wanted to better understand the market opportunity for this potentiator and therefore asked Alacrita to conduct a market research exercise in the context of nosocomial infections caused by three Gram-negative pathogens: Acinetobacter baumannii, Stenotrophomonas maltophilia and Pseudomonas aeruginosa. Solu

Join for free to read